732308-82-6

Basic information

• Product Name: 2-(4-(tert-butoxycarbonyl)phenyl)acetic acid
• Synonyms: 2-(4-(tert-butoxycarbonyl)phenyl)acetic acid
• CAS NO: 732308-82-6
• Molecular Formula: C₁₃H₁₆O₄
• Molecular Weight: 236.26374
• Mol File: 732308-82-6.mol

Chemical Properties

• Boiling Point: 371.0±25.0 °C(Predicted)
• Appearance: /
• Density: 1.156±0.06 g/cm3(Predicted)
• PKA: 4.05±0.10(Predicted)
• CAS DataBase Reference: 2-(4-(tert-butoxycarbonyl)phenyl)acetic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-(tert-butoxycarbonyl)phenyl)acetic acid(732308-82-6)
• EPA Substance Registry System: 2-(4-(tert-butoxycarbonyl)phenyl)acetic acid(732308-82-6)

Safety Data

• Hazardous Substances Data: 732308-82-6(Hazardous Substances Data)

Upstream product

• 87524-66-1 4-(methoxycarbonylmethyl)benzoic acid 
• 115-11-7 isobutene 
• 201230-82-2 carbon monoxide 
• 108052-76-2 4-(bromomethyl)benzoic acid 1,1-dimethylethyl ester 
• 59247-47-1 tert-butyl-4-bromobenzoate 
• 934737-91-4 tert-butyl 4-(2-methoxy-2-oxoethyl)benzoate 
• 918628-81-6 2-(4-tert-butoxycarbonyl-phenyl)-malonic acid dimethyl ester 

Downstream Products

• 1003315-39-6 tert-butyl 4-[2-(4-ethyl-4-oxido-1,4-azaphosphinan-1-yl)-2-oxoethyl]benzoate 
• 149325-40-6 tert-butyl 4-(2-hydroxyethyl)benzoate 
• 936755-34-9 tert-butyl 4-{[5-(2-methoxyphenyl)-1,3,4-oxadiazol-2-yl]methyl}benzoate 
• 936755-32-7 4-{[5-(2-methoxyphenyl)-1,3,4-oxadiazol-2-yl]methyl}benzoic acid 
• 1080060-07-6 tert-butyl 4-{2-[methoxy(methyl)amino]-2-oxoethyl}benzoate 
• 934737-91-4 tert-butyl 4-(2-methoxy-2-oxoethyl)benzoate 
• 936755-33-8 tert-butyl 4-{2-[2-(2-methoxybenzoyl)hydrazin]-2-oxoethyl}benzoate 

Relevant articles and documents

Prodrug Strategies to Improve the Solubility of the HCV NS5A Inhibitor Pibrentasvir (ABT-530)

A research program to discover solubilizing prodrugs of the HCV NS5A inhibitor pibrentasvir (PIB) identified phosphomethyl analog 2 and trimethyl-lock (TML) prodrug 9. The prodrug moiety is attached to a benzimidazole nitrogen atom via an oxymethyl linkage to allow for rapid and complete release of the drug for absorption following phosphate removal by intestinal alkaline phosphatase. These prodrugs have good hydrolytic stability properties and improved solubility compared to PIB, both in aqueous buffer (pH 7) and FESSIF (pH 5). TML prodrug 9 provided superior in vivo performance, delivering high plasma concentrations of PIB in PK studies conducted in mice, dogs, and monkeys. The improved dissolution properties of these phosphate prodrugs provide them the potential to simplify drug dosage forms for PIB-containing HCV therapy.

Pd(OH)2/C, a Practical and Efficient Catalyst for the Carboxylation of Benzylic Bromides with Carbon Monoxide

A simple, efficient, cheap, and broadly applicable system for the carboxylation of benzylic bromides with carbon monoxide and water is reported. Upon simple reaction with only 2.5 wt % of Pearlman's catalyst and 10 mol % of tetrabutylammonium bromide in tetrahydrofuran at 110 °C for 4 h, a range of benzylic bromides can be smoothly converted to the corresponding arylacetic acids in good to excellent yields after simple extraction and acid-base wash. The reaction was found to be broadly applicable, scalable, and could be successfully extended to the use of ex situ-generated carbon monoxide and applied to the synthesis of the nonsteroidal anti-inflammatory drug diclofenac.

ALDOSTERONE SYNTHASE INHIBITORS

The present invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof, wherein X, R1, R2 and R3 are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Dicarboxylic Acid Derivatives and their Use

The present application relates to novel dicarboxylic acid derivatives, process for their preparation, their use for the treatment and/or prophylaxis of diseases, and their use for producing medicaments for the treatment and/or prophylaxis of diseases, es

Inhibitors of Histone Deacetylase

The present invention relates to a novel class of compounds. These compounds can inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compounds of the invention may also be useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases. The present invention further provides pharmaceutical compositions comprising the compounds of the instant invention and sale dosing regimens of these pharmaceutical compositions, which are easy to follow, and which result in a therapeutically effective amount of these compounds in vivo.

PHOSPHORUS DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS

The present invention relates to a novel class of phosphorus derivatives. The phosphorus compounds can be used to treat cancer. The phosphorus compounds can also inhibit histone deacetylase and are suitable for use in selectively inducing terminal differe

HISTONE DEACETYLASE INHIBITORS WITH ARYL-PYRAZOLYL MOTIFS

The present invention relates to a novel class of histone deacetylase inhibitors with aryl-pyrazolyl motifs. The compounds of this invention can be used to treat cancer. The compounds of this invention are suitable for use in selectively inducing terminal

CARBAMIC ACID COMPOUNDS COMPRISING AN ESTER OR KETONE LINKAGE AS HDAC INHIBITORS

This invention pertains to certain carbamic acid compounds of the formula (I), which inhibit HDAC (histone deacetylase) activity: wherein: J is a linking functional group and is independently: -O-C(=O)- or -C(=O)-O- or - C(=O)-; Cy is a cyclyl group and is independently: C3-20carbocyclyl, C3-20heterocyclyl, or C5-20aryl; and is optionally substituted; Q1 is a cyclyl leader group, and is independently a divalent bidentate group obtained by removing two hydrogen atoms from a ring carbon atom of a saturated monocyclic hydrocarbon having from 4 to 7 ring atoms, or by removing two hydrogen atoms from a ring carbon atom of saturated monocyclic heterocyclic compound having from 4 to 7 ring atoms including 1 nitrogen ring atom or 1 oxygen ring atom; and is optionally substituted; Q2 is an acid leader group, and is independently: C1-8alkylene; and is optionally substituted; or: Q2 is an acid leader group, and is independently: C5-20arylene; C5-20arylene-C1-7alkylene; C1-7alkylene-C5-20arylene; or C1-7alkylene-C5-20arylene-C1-7alkylene; and is optionally substituted; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit HDAC,and in the treatment of conditions mediated by HDAC, cancer, proliferative conditions, psoriasis, etc.